Clinical Trial

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

Study acronym: RAINFOL-02
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo.
Protocol Amendment History 2 changes
notable Enrollment increased: 448 -> 530 participants 2026-06-09
notable Enrollment reduced: 530 -> 448 participants 2026-05-28
Trial Details
NCT Number NCT06619236
Lead Sponsor Genmab
Conditions Platinum-resistant Ovarian Cancer
Enrollment 530 participants
Start Date 2025-02-07
Primary Completion 2027-02 (estimated)
Study Completion 2028-05-23 (estimated)
Updated on ClinicalTrials.gov 2026-08-12